Mr Kabeer Aziz | Principal
Adjuvant Capital

Mr Kabeer Aziz, Principal, Adjuvant Capital

Kabeer co-founded Adjuvant Capital after three years with the Global Health Investment Fund (GHIF). While at GHIF he was responsible for sourcing and analyzing new opportunities, including co-leading the fund’s investments in Univercells, Access Bio, and Atomo Diagnostics. Currently, at Adjuvant Capital, he has led and managed investments in AN2 Therapeutics (Board Member) and Themis Bioscience (Board Observer).

Prior to GHIF, Kabeer was an investment professional at Metalmark Capital, a private equity fund in New York, where he focused primarily on medical device investments. Kabeer also spent time at Greenhill & Co., a boutique investment bank, where he advised on M&A transactions in the biopharmaceutical and medical technology sectors. He graduated with honors from the Stern School of Business at New York University with a BS in Finance & Economics.


Pre-congress Workshops, April 6 @ 10:00


The enthusiasm for investing in biologics, including vaccines, has grown significantly over the last decade with the advent of novel platform technologies and new therapeutic modalities but raising capital remains a challenge.Topics include:
  • What is the average cost and time to develop a new vaccine?
  • How have biotechs raised money when they don’t have access to these funds? How was it done? How hard was it? (Sanaria)
  • Funding needs and research and development gaps for achieving vaccine research and development preparedness targets
  • Promoting private investment in vaccine development
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates